ALNT · Allient Inc.

The thesis

Allient's record order book still supports the business, but the shares have kept sliding since JPMorgan's valuation downgrade, and the third-quarter report after the close on 4 November 2026 decides whether orders and cash flow justify the price. The adjusted close was $94.04 on 27 October 2026, 20.7% below the $118.63 52-week high and just above the $94.18 close of 10 September 2026 from which the September rally began.

Nothing in the operating numbers has changed since the 5 August 2026 release. JPMorgan analyst Tomohiko Sano cut the rating to neutral from overweight on 13 October 2026, kept a $120 price target and cited a rally of about 90% since May and roughly 21 times next-twelve-months enterprise value to EBITDA (earnings before interest, taxes, depreciation and amortisation), per Investing.com and MarketBeat.

The narrative is maturing: the order story is well known, the shares have given back most of the September move since the 13 October 2026 downgrade, and the next measurement is one week away. The 14-day relative strength index (RSI) was 30.2 on 27 October 2026, at the level conventionally read as oversold.

Bullish and bearish views on Allient Inc.

The bull case on Allient Inc. (ALNT), in brief: Orders ran well ahead of shipments. The bear case: Cash conversion is still unproven.

Bull case

• Orders ran well ahead of shipments. Second-quarter 2026 orders of $201.3 million against a 1.31x book-to-bill, reported 5 August 2026, left a $298.0 million backlog. Management said at its 10 September 2026 conference presentation that most backlog converts to revenue within three to nine months.
• The last quarter beat estimates. MarketBeat reports second-quarter adjusted earnings per share of $0.80 against a $0.61 consensus, and revenue of $153.77 million against $145.68 million expected. Gross margin was 34.9%, up 170 basis points year over year, per the 5 August 2026 release.
• The price has moved toward the pre-rally level. The close of $94.04 on 27 October 2026 sits below JPMorgan's $120 target, which the firm kept on 13 October 2026 when it cut the rating on valuation alone.
• second-quarter orders were up 30% from that, per company releases.

Bear case

• Cash conversion is still unproven. Benzinga and StockStory recaps of the 5 August 2026 results put second-quarter free cash flow at negative $18.31 million. A second negative quarter would weaken the claim that orders turn into cash.
• Valuation was the stated reason for caution. JPMorgan cited about 21 times next-twelve-months EV/EBITDA on 13 October 2026. MarketBeat's price-to-earnings ratio was 60.18 on the same date.
• Insiders sold into strength. A Form 4 filed 12 August 2026 shows trusts of chief executive Richard Warzala sold 70,000 shares on 10 August 2026 at $112.49 to $115.765. Schedule 13D holder Juniper reported selling 165,991 shares between 11 August 2026 and 13 August 2026.
• Ratings drifted lower. Wall Street Zen cut the stock to buy from strong-buy on 19 September 2026, and Weiss Ratings cut it to hold (c+) on 21 September 2026. MarketBeat's consensus target was $84.00 on 13 October 2026, from four buy and two hold ratings.

Price setup

The adjusted daily close was $94.04 on 27 October 2026, against $99.13 on 14 October 2026 and $106.38 on 12 October 2026, the last close before the downgrade (MarketBeat). The 52-week high is $118.63. The shares were up 9.1% over three months to 27 October 2026.

The September rally started from the $94.18 close of 10 September 2026, and the latest close is within a few cents of that level. MarketBeat listed the 200-day moving average at $87.60 on 13 October 2026, about 7% below the latest close; the 50-day average was $103.52, above it.

Crowding evidence is limited to the earnings date and the August insider and 13D-holder sales. MarketBeat put average daily volume near 223,000 shares in September 2026, so a single large filing or report can move the shares sharply.

Catalysts, next 30 days

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• 4 November 2026, after the market close: third-quarter 2026 results. Allient has scheduled the release, per a scanx.trade report of the company's calendar notice. The report shows whether book-to-bill stays above 1.0x, backlog holds above $298.0 million and free cash flow turns positive. (passed 2d ago)
• 5 November 2026, 10:00 a.m. Eastern: earnings call. Management commentary on how fast the backlog converts to revenue and on margin direction is the second half of the test. (passed 1d ago)

What would change the view

The case breaks if third-quarter 2026 book-to-bill falls below 1.0x or backlog drops below the $298.0 million reported for the second quarter. Free cash flow staying negative for a second quarter would weaken it further. On price, a daily close below $94, which is the area of the 10 September 2026 close of $94.18 that preceded the September rally, would show the rally fully unwound.

A third-quarter report with orders above revenue, backlog above $298.0 million and positive free cash flow would address both open questions in the bear case. It would leave valuation as the remaining argument.

What it trades with

Allient makes motion-control components sold into industrial, vehicle, medical and aerospace-and-defense end markets, so its orders follow industrial capital spending more than any single customer. Coverage is thin at about six analysts, and the shares trade on company-specific reports and rating changes more than on index moves. Other small and mid-cap industrial suppliers with similar order-driven rallies share the valuation risk JPMorgan described.